bioRxivImmunologyPreprint
Chimeric Antigen Receptor Macrophages Target and Resorb Amyloid Plaques in a Mouse Model of Alzheimer's Disease
Q. Pan, P. Yan, A. B. Kim, Q. Xiao, G. Pandey, H. Haecker, S. Epelman, A. Diwan, J.-M. Lee, C. J. DeSelm
Abstract
Substantial evidence suggests a role for immunotherapy in treating Alzheimers disease (AD). Several monoclonal antibodies targeting aggregated forms of beta amyloid (A{beta}), have been shown to reduce amyloid plaques and in some cases, mitigate cognitive decline in early-stage AD patients. We sought to determine if genetically engineered macrophages could improve the targeting and degradation of amyloid plaques. Chimeric antigen receptor macrophages (CAR-Ms), which show promise as a cancer treatment, are an appealing strategy to enhance target recognition and phagocytosis of amyloid plaques in AD. We genetically engineered macrophages to express a CAR containing the anti-amyloid antibody aducanumab as the external domain and the Fc receptor signaling domain internally. CAR-Ms recognize and degrade A{beta} in vitro and on APP/PS1 brain slices ex vivo; however, when injected intrahippocampally, these first-generation CAR-Ms have limited persistence and fail to reduce plaque load. We overcame this limitation by creating CAR-Ms that secrete M-CSF and self-maintain without exogenous cytokines. These CAR-Ms have greater survival in the brain niche, and significantly reduce plaque load locally in vivo. These proof-of-principle studies demonstrate that CAR-Ms, previously only applied to cancer, may be utilized to target and degrade unwanted materials, such as amyloid plaques in the brains of AD mice. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=120 SRC="FIGDIR/small/538637v2_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@561cd6org.highwire.dtl.DTLVardef@17f362forg.highwire.dtl.DTLVardef@be83ecorg.highwire.dtl.DTLVardef@1c735ce_HPS_FORMAT_FIGEXP M_FIG Amyloid targeting CAR Macrophages engineered to secrete M-CSF promote their own local survival and expansion while resorbing amyloid plaques in the brains of Alzheimers disease APP/PS1 mice, resulting in significant local clearance of amyloid plaques of all sizes. C_FIG
- organism: mouse
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Attenuating amyloid-beta pathology in mice with in situ programmed astrocytes
Lun Zhang, Shuai Lü, … Rui‐tian Liu·bioRxiv·Oct 30, 2023
- Anti-Aβ immunotherapy-mediated amyloid clearance attenuates microglial activation without inducing exhaustion at residual plaques
Lis de Weerd, Selina Hummel, … Christian Haass·bioRxiv·Apr 10, 2025
- Expression of amyloid-β antibody via AAV of CNS tropism alleviates Alzheimer's disease in mice
Zhong‐Min Dai, Min Jiang, … Mengsheng S. Qiu·bioRxiv·Mar 20, 2026
- Functional border-associated macrophages limit Alzheimer's Disease progression
Drew I. Adler, Natália Pinheiro-Rosa, … Juan J. Lafaille·bioRxiv·Feb 3, 2026
- Chimeric Antigen Receptors Discriminate Between Tau and Distinct Amyloid-Beta Species
Cynthia J. Siebrand, Nicholas J. Bergo, … Chaska C. Walton·Journal of Translational MedicinePeer-reviewed·May 30, 2025
- Aβ Antibodies Target Not Only Amyloid Plaques But Also Distinct Brain Cells And Vessels
Gehua Wen, Nils Lindblom, … Gunnar K. Gouras·Alzheimer s & DementiaPeer-reviewed·Jan 1, 2026